FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2887324472> ?p ?o ?g. }

• W2887324472 abstract "Introduction and objectives: Prostate cancer is the most frequently diagnosed non-skin malignancy and third leading cause of cancer related deaths among men in the United States. Currently, early detected organ confined prostate cancer (CaP) is managed by active surveillance, surgery or radiation therapy. A significant subset of patients (20% to 40%) experience biochemical recurrence after definitive treatment. New AR axis inhibitors (abiraterone and enzalutamide) are leading to significant improvements in treatment of late stages of CaP. However, sustained therapeutic response remains a challenge due to high mutation load at late stages of the disease. Thus, there is an urgent need for evaluating new therapeutic targets for early stages of CaP. ERG oncoprotein and ERG dependent pathways are promising targets for early stage cancer therapy. Previously identified ERGi-USU from our laboratory, demonstrated remarkable exclusivity for inhibiting ERG protein and cell growth of ERG positive tumor cells in both in vitro and in vivo. With comprehensive structure activity relationship (SAR) studies, we generated new derivatives with substituents around the core structure to further enhance efficacy. Methods: Cell growth inhibition of small molecules was validated with established prostate cancer cell lines and normal prostate/endothelial derived cell panel. Preferential species-specific binding of ERGi-USU to human RIOK2 was confirmed by tryptophan fluorescence quenching assay. Result: Based on SAR of the parental ERGi-USU, 90 new ERGi-USU derivatives were designed using structure based predictions. Of these, 37 compounds were prioritized for chemical synthesis and biological evaluations using assays that were developed earlier in our laboratory. We completed primary screen of these compounds in cell culture models. Among these one compound (ERGi-USU-6) inhibited the growth of ERG positive prostate cancer cells with remarkable improvement IC50=70 nM. This value is in the range of current FDA approved drugs. The result also confirmed the high selectivity of ERGi-USU-6 for the inhibition of ERG positive cancer cell growth. Further, mechanistic studies revealed ERGi-USU binding and disruption of the atypical RIOK2 kinase basic function of ribosome biogenesis, due to initiation of ribosomal stress, cell cycle arrest and apoptosis in ERG positive VCaP cells. We also demonstarte preferential binding of ERGi-USU to human RIOK2 by tryptophan fluorescence quenching assay. Conclusion: The ERGi-USU-6, derivative of ERGi-USU showed improved efficacy in selectively inhibiting the growth of ERG positive cancer cells. Since ERG is a prostate cancer causing oncogene that affects approximately one third of CaP patients world-wide, early therapeutic intervention with ERGi-USU derivatives may prevent the development of late stage disease in prostate cancer patients. Citation Format: Charles Peter Xavier, Ahmed A. Mohamed, Nishat Seraj, Vineet Kumar, Taduru Sreenath, Inger L. Rosner, Gyorgy Petrovics, Meera Srivastava, Clifton L. Dalgard, Sanjay V. Malhotra, Nicole A. LaRonde, Albert Dobi, Shiv Srivastava. Synthesis and evaluation of derivatives of selective inhibitor ERGi USU, for ERG-positive prostate cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 2797." @default.
• W2887324472 created "2018-08-22" @default.
• W2887324472 creator A5001881989 @default.
• W2887324472 creator A5002030822 @default.
• W2887324472 creator A5007936453 @default.
• W2887324472 creator A5011312688 @default.
• W2887324472 creator A5042505549 @default.
• W2887324472 creator A5045582598 @default.
• W2887324472 creator A5046265322 @default.
• W2887324472 creator A5054809967 @default.
• W2887324472 creator A5057889514 @default.
• W2887324472 creator A5062324742 @default.
• W2887324472 creator A5076217823 @default.
• W2887324472 creator A5079043204 @default.
• W2887324472 creator A5091150805 @default.
• W2887324472 date "2018-07-01" @default.
• W2887324472 modified "2023-10-14" @default.
• W2887324472 title "Abstract 2797: Synthesis and evaluation of derivatives of selective inhibitor ERGi USU, for ERG-positive prostate cancer cells" @default.
• W2887324472 doi "https://doi.org/10.1158/1538-7445.am2018-2797" @default.
• W2887324472 hasPublicationYear "2018" @default.
• W2887324472 type Work @default.
• W2887324472 sameAs 2887324472 @default.
• W2887324472 citedByCount "1" @default.
• W2887324472 countsByYear W28873244722019 @default.
• W2887324472 crossrefType "proceedings-article" @default.
• W2887324472 hasAuthorship W2887324472A5001881989 @default.
• W2887324472 hasAuthorship W2887324472A5002030822 @default.
• W2887324472 hasAuthorship W2887324472A5007936453 @default.
• W2887324472 hasAuthorship W2887324472A5011312688 @default.
• W2887324472 hasAuthorship W2887324472A5042505549 @default.
• W2887324472 hasAuthorship W2887324472A5045582598 @default.
• W2887324472 hasAuthorship W2887324472A5046265322 @default.
• W2887324472 hasAuthorship W2887324472A5054809967 @default.
• W2887324472 hasAuthorship W2887324472A5057889514 @default.
• W2887324472 hasAuthorship W2887324472A5062324742 @default.
• W2887324472 hasAuthorship W2887324472A5076217823 @default.
• W2887324472 hasAuthorship W2887324472A5079043204 @default.
• W2887324472 hasAuthorship W2887324472A5091150805 @default.
• W2887324472 hasConcept C103796816 @default.
• W2887324472 hasConcept C118487528 @default.
• W2887324472 hasConcept C121608353 @default.
• W2887324472 hasConcept C126322002 @default.
• W2887324472 hasConcept C143998085 @default.
• W2887324472 hasConcept C207001950 @default.
• W2887324472 hasConcept C2776235491 @default.
• W2887324472 hasConcept C2779399171 @default.
• W2887324472 hasConcept C2780192828 @default.
• W2887324472 hasConcept C2780827179 @default.
• W2887324472 hasConcept C502942594 @default.
• W2887324472 hasConcept C54355233 @default.
• W2887324472 hasConcept C71924100 @default.
• W2887324472 hasConcept C86803240 @default.
• W2887324472 hasConcept C96232424 @default.
• W2887324472 hasConceptScore W2887324472C103796816 @default.
• W2887324472 hasConceptScore W2887324472C118487528 @default.
• W2887324472 hasConceptScore W2887324472C121608353 @default.
• W2887324472 hasConceptScore W2887324472C126322002 @default.
• W2887324472 hasConceptScore W2887324472C143998085 @default.
• W2887324472 hasConceptScore W2887324472C207001950 @default.
• W2887324472 hasConceptScore W2887324472C2776235491 @default.
• W2887324472 hasConceptScore W2887324472C2779399171 @default.
• W2887324472 hasConceptScore W2887324472C2780192828 @default.
• W2887324472 hasConceptScore W2887324472C2780827179 @default.
• W2887324472 hasConceptScore W2887324472C502942594 @default.
• W2887324472 hasConceptScore W2887324472C54355233 @default.
• W2887324472 hasConceptScore W2887324472C71924100 @default.
• W2887324472 hasConceptScore W2887324472C86803240 @default.
• W2887324472 hasConceptScore W2887324472C96232424 @default.
• W2887324472 hasLocation W28873244721 @default.
• W2887324472 hasOpenAccess W2887324472 @default.
• W2887324472 hasPrimaryLocation W28873244721 @default.
• W2887324472 hasRelatedWork W1571614507 @default.
• W2887324472 hasRelatedWork W1964128524 @default.
• W2887324472 hasRelatedWork W2041633194 @default.
• W2887324472 hasRelatedWork W2045315430 @default.
• W2887324472 hasRelatedWork W2101507995 @default.
• W2887324472 hasRelatedWork W2135658869 @default.
• W2887324472 hasRelatedWork W2165919621 @default.
• W2887324472 hasRelatedWork W2626317664 @default.
• W2887324472 hasRelatedWork W2915735309 @default.
• W2887324472 hasRelatedWork W3016632711 @default.
• W2887324472 isParatext "false" @default.
• W2887324472 isRetracted "false" @default.
• W2887324472 magId "2887324472" @default.
• W2887324472 workType "article" @default.